50
Participants
Start Date
March 31, 2012
Primary Completion Date
March 24, 2017
Study Completion Date
March 24, 2017
zolinza/vorinostat
orally once per day (suspension of 50mg/ml or capsules of 100 mg vorinostat); starting dose will be 180 mg/m²/d; escalated with increments of 50 mg/m²/d every two weeks until dose limiting toxicity (grade 3 or 4 toxicity according to CTC) occurs or up to a maximum dose of 580 mg/m²/d; This dose will then be applied for 3 months. Patients without progression at first response evaluation will continue treatment for a maximum of 9 months.
Department of Pediatric Oncology and Hematology University Hospital Eppendorf (UKE), Hamburg
Prof. Hess Childrens's Hospital, Pediatric Oncology and Hematology, Bremen
University Children's Hospital, Pediatric Oncology and Hematology, MHH, Hanover
University Childrens's Hospital, Pediatric Oncology and Hematology, Essen
Department of Pediatric Oncology and Hematology University Children's Hospital, Münster
University Children's Hospital, Pediatric Oncology and Hematology, Cologne
Clinic for Pediatric Oncology, Hematology, Immunology and Clinical Cooperation Unit Pediatric Oncology, Heidelberg
University Children's Hospital, Clinic IV, Freiburg im Breisgau
Childrens's Hospital, Pediatric Oncology and Hematology, Augsburg
University Childrens's Hospital, Pediatric Oncology and Hematology, Jena
University Hospital Heidelberg
OTHER
Merck Sharp & Dohme LLC
INDUSTRY
National Center for Tumor Diseases, Heidelberg
OTHER